Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease

Alzheimer's and Dementia

Volumn 9, Issue 4, 2013, Pages

  Herrup, Karl ^a   Carrillo, Maria C ^b   Schenk, Dale ^c   Cacace, Angela ^d   DeSanti, Susan ^e   Fremeau, Robert ^f   Bhat, Ratan ^g   Glicksman, Marcie ^h   May, Patrick ⁱ   Swerdlow, Russell ^j   Van Eldik, Linda J ^k   Bain, Lisa J ^l   Budd, Samantha ^g  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b ALZHEIMER'S ASSOCIATION   (United States)

^c ELAN PHARMACEUTICALS   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e GE HEALTHCARE   (United States)

^f AMGEN INC   (United States)

^g ASTRAZENECA   (United Kingdom)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF KENTUCKY   (United States)

^l Independent Medical Writer   (United States)

more..

Author keywords

Alzheimer's disease; Amyloid; Autophagy; Cell cycle; Inflammation; Metabolism; Mitochondria; Neuroinflammation; Non amyloid targets; Tau; Therapeutics

Indexed keywords

AMYLOID; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; CELL CYCLE; CHRONIC INFLAMMATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FOOD AND DRUG ADMINISTRATION; GENETICS; HUMAN; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

EID: 84882340417     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.01.017     Document Type: Article

References (59)

1. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9:1-11e13.
2. Schenk D, Carrillo MC, Trojanowski JQ. Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery. Alzheimers Dement 2006;2:275-81.
3. Lee VM, Daughenbaugh R, Trojanowski JQ. Microtubule stabilizing drugs for the treatment of Alzheimer's disease. Neurobiol Aging 1994;15:S87-9.
4. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010;30:13861-6.
5. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 2012;32:3601-11.
6. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 2005;102:227-31.
7. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Psychiatrie Psychisch-Gerichtliche Med 1907;64:146-8.
8. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012;71:266-73.
9. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-46.
10. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011.
11. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
12. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-35.
13. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010;5:e13950.
14. Naj AC, Jun G, BeechamGW,Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43:436-41.
15. Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 2010;6.
16. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71:1057-64.
17. Moulton PV, Yang W. Air pollution, oxidative stress, and Alzheimer's disease. J Environ Public Health 2012;2012:472751.
18. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010; 141:1146-58.
19. Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J Neurosci 2011;31:7817-30.
20. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloidbeta, and effects on cognitive impairments. J Biol Chem 2010; 285:13107-20.
21. Herrup K. Reimagining Alzheimer's disease: An age-based hypothesis. J Neurosci 2010;30:16755-62.
22. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 2001;21:2661-8.
23. Feddersen RM, Ehlenfeldt R, Yunis WS, Clark HB, Orr HT. Disrupted cerebellar cortical development and progressive degeneration of Purkinje cells in SV40 T antigen transgenic mice. Neuron 1992; 9:955-66.
24. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, et al. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 2009; 119:3692-702.
25. Herrup K. The contributions of unscheduled neuronal cell cycle events to the death of neurons in Alzheimer's disease. Front Biosci (Elite Ed) 2012;4:2101-9.
26. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986;83:4913-7.
27. Kanaan NM, Morfini GA, Lapointe NE, Pigino GF, Patterson KR, SongY, et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 2011;31:9858-68.
28. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, et al. Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease. J Biol Chem 2011;286:23063-76.
29. Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini G, et al. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 2011;50:10300-10.
30. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003; 278:45937-45.
31. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 2004;89:1313-7.
32. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010;67:953-66.
33. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011;2:252.
34. Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease? J Cell Biol 1996;132:413-25.
35. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118:658-67.
36. Chai X,Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J Biol Chem 2011;286:34457-67.
37. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007;117:648-58.
38. Jinwal UK, O'Leary JC 3rd, Borysov SI, Jones JR, Li Q, Koren J 3rd, et al. Hsc70 rapidly engages tau after microtubule destabilization. J Biol Chem 2010;285:16798-805.
39. Abisambra JF, Jinwal UK, Suntharalingam A, Arulselvam K, Brady S, Cockman M, et al. DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau. J Mol Biol 2012.
40. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909-13.
41. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012;73:685-97.
42. Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011;286:15317-31.
43. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Transcellular propagation of tau aggregation by fibrillar species. J Biol Chem 2012.
44. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42-52.
45. Wu Q, Combs C, Cannady SB, Geldmacher DS, Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging 2000;21:797-806.
46. Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, et al. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. Neuron 2011;71:833-44.
47. Fuller S, Steele M, Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease: Do they neglect their neurosupportive roles? Mutat Res 2010;690:40-9.
48. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009;18:R169-76.
49. Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, et al. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 2010;30:2636-49.
50. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 2010;37:503-9.
51. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease: A brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2:a006346.
52. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al. Locus coeruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 2010; 107:6058-63.
53. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004;63:8-20.
54. Swerdlow RH. Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharmacol Des 2011;17:3356-73.
55. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-38.
56. Schenk D, Barbour R, DunnW, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
57. Greenberg SM, Bacskai BJ, Hyman BT. Alzheimer disease's double-edged vaccine. Nat Med 2003;9:389-90.
58. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 2012; 32:7137-45.
59. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;3:1.